S2408 Pre-launch Meeting

S2408: A Randomized Phase III Multicenter Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula

THURSDAY, APRIL 4 • 2 – 3 PM PT • BECKLER ROOM (302), LEVEL 3

The S2408 pre-launch meeting will introduce participants to this recently approved phase III multicenter trial for patients undergoing distal pancreatectomy for cancer or a pre-malignant pancreatic lesion.

S2408 was recently approved by the NCI’s Division of Cancer Prevention to evaluate whether a single dose of the somatostatin analogue lanreotide may prevent the “Achilles Heel” of pancreatic surgery – postoperative pancreatic fistula (POPF). POPF delays chemotherapy, increases healthcare costs, and decreases survival.

THE SESSION WILL REVIEW:

- Trial background, eligibility criteria and treatment plan
- Placebo plan (a SWOG-first!)
- Biospecimen collection
- Patient reported outcomes

Surgeons, medical oncologists, and oncology research professionals are encouraged to attend and learn more about this unique SWOG trial!

ATTEND IN-PERSON OR VIRTUALLY.